Headquartered in Irving, TX Fiscal year ends March NYSE: MCK mckesson.com
McKesson Corporation is a diversified healthcare services company that partners with biopharma companies, care providers, pharmacies, manufacturers, and governments to deliver pharmaceutical distribution, oncology and multispecialty solutions, prescription technology services, and medical-surgical supply distribution. The company operates four reportable segments: North American Pharmaceutical (its largest segment by revenue, distributing branded, generic, specialty, and biosimilar pharmaceuticals), Oncology & Multispecialty (providing provider solutions, specialty drug distribution, and practice management for oncology and other specialty practices), Prescription Technology Solutions (offering third-party logistics, access and adherence solutions, and technology services to biopharma companies), and Medical-Surgical Solutions (distributing medical-surgical supplies and specialty pharmaceuticals to alternate sites of care, which is being separated into a standalone public company named Wellverse). McKesson serves as a critical intermediary in the U.S. healthcare supply chain, handling prescription transaction volumes and specialty product distribution at scale. Updated
Accenture opened 22% higher, a move you almost never see from a mega-cap IT services name, while Corteva dropped 82% to $13.96 at the other end of the board. Synopsys, McKesson and IBM round out a gainers list that is all up at least 5.9%.
One Number: $7.2 Million in Revenue Per Employee NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) now brings in about $7.2 million in revenue for each person on its payroll. That figure comes from…
All the major Wall Street firms we cover here at 24/7 Wall St. have a list of the top stock picks for their institutional and retail clients to invest in. Typically, these…
William Blair launched coverage of Cardinal Health (NYSE:CAH | CAH Price Prediction) with an Outperform rating today, framing the pharma distributor as a durable franchise with specialty-led upside. The firm simultaneously initiated…
Somehow, members of Congress have turned relatively modest salaries into impressive investment portfolios while the rest of us grind it out in the market. For years, questions have swirled around lawmakers buying…
UnitedHealth Group (NYSE:UNH | UNH Price Prediction) has faced severe headwinds in 2025, with its stock plummeting over 50% from its April high. This decline was driven by a rare first-quarter earnings…
Investing in dividend growth stocks is a smart, reliable way to build passive income that lasts a lifetime, and it’s worth considering if you’re eyeing financial freedom. These are companies that have…
These four Jim Cramer stock picks had strong November performances and are likely to follow through in December.
Selecting stocks for the long haul can be a challenge. Here is what could be the best-performing stock in 2030 and why.
While dividend stock investing is one of the best strategies an investor can pursue to create phenomenal wealth, chasing yield can undermine the entire effort. Buying dividend stocks simply because the yields…
These five top companies are Wall Street favorites and are expected to raise their dividends this week, showing that they are doing well and have the earnings and cash flow strength to…
Monday's top analyst upgrades and downgrades included BlackBerry, Cardinal Health, Comstock Resources, Howmet Aerospace, JD.com, Pacific Biosciences of California, Restaurant Brands, Tenaris and Wendy’s.
Wednesday's top analyst upgrades and downgrades included Altria, Apple, Bath & Body Works, BorgWarner, Chevron, Exxon Mobil, FedEx, Occidental Petroleum, Peabody Energy, Plug Power, Rio Tinto, Target, United Parcel Service, Vale and…
Monday's top analyst upgrades and downgrades included Bill.com, Cigna, ConocoPhillips, Estee Lauder, Fortinet, Microchip Technology, Pfizer, Skyworks Solutions, Snap, Snowflake, VICI Properties and Wipro.
Monday's top analyst upgrades and downgrades included Airbnb, AT&T, Duke Energy, Etsy, FirstEnergy, Gap, IBM, KeyCorp, Kohl's, Las Vegas Sands, Nvidia, Starbucks, Trade Desk and Visa.
In a move that investors looking for more defensive ideas should applaud, the analysts at Goldman Sachs have added Bristol-Myers Squibb to the Americas Conviction List. Plus, here are four additional health…
McKesson Corporation is a diversified healthcare services company that partners with biopharma companies, care providers, pharmacies, manufacturers, and governments to deliver pharmaceutical distribution, oncology and multispecialty solutions, prescription technology services, and medical-surgical supply distribution.
24/7 Wall St.'s 12-month price target for MCK is $1,067.50, rated Buy. The Wall Street consensus target is $979.36. MCK price prediction →
